13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001807489
Total reported value
$47.2M
$47.2M
9 檔
133.1%
As reported in its official Q3 2025 Form 13F filing, M28 Capital Management LP's tracked investment portfolio stood at $47.2M with 9 total positions.
In Q3 2025, M28 Capital Management LP adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | WVE | Wave Life Sciences Ltd. | Stock-Other | 60.97% | -5.30% | — | |
| 2 | IVVD | Invivyd Inc | Stock-Other | 14.96% | -5.24% | — | |
| 3 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 8.58% | +4.83% | — | |
| 4 | GUTS | Fractyl Health Inc | Stock-Other | 4.34% | +1.55% | — | |
| 5 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 3.42% | +2.08% | — | |
| 6 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 3.19% | +0.56% | — | |
| 7 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.85% | +0.13% | — | |
| 8 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.41% | +1.37% | — | |
| 9 | CRIS | Curis Inc | Stock-Other | 1.27% | +0.03% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IVVD | Invivyd Inc | +7.3% | — | Unchanged |
| 2 | ARWR | Arrowhead Pharmaceuticals In | +2.2% | — | Unchanged |
| 3 | ✓ | Proqr Therapeutics N.v. | +1.3% | — | Unchanged |
| 4 | GUTS | Fractyl Health Inc | +1.3% | — | Unchanged |
| 5 | SLN | Silence Therapeutics Plc-adr | +0.7% | — | Unchanged |
| 6 | TGTX | Tg Therapeutics Inc | -0.2% | — | Unchanged |
| 7 | CRIS | Curis Inc | -0.2% | — | Unchanged |
| 8 | RCKT | Rocket Pharmaceuticals Inc | -1.7% | — | Unchanged |
| 9 | WVE | Wave Life Sciences Ltd. | -1.8% | — | Unchanged |
| 10 | BBIO | Bridgebio Pharma Inc | — | EXIT | Sold out |
| 11 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, M28 Capital Management LP reported a total U.S. public equity portfolio value of $47.2M across 9 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including WVE, IVVD, TGTX) accounted for 133.1% of total reported equity market value during Q3 2025.
Top Position Liquidated / Trimmed
BBIO
前期市值: $4.2M
During Q3 2025, M28 Capital Management LP's top holdings by market value included WVE (61.0%)、IVVD (15.0%)、TGTX (8.6%). The largest single position, WVE, represented 61.0% of total portfolio value.
In Q3 2025, M28 Capital Management LP made 2 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.